Akebia Therapeutics, Inc. (AKBA)

↓ Download CSV

CIK 0001517022 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Akebia Therapeutics, Inc. reported revenue of $236.20M, up 47.5% from the prior year. The company ran a net loss, with a net margin of -2.3%. It held $376.56M in total assets against $343.95M in total liabilities.

Key ratios (FY2025)

9.9%
Operating margin
-2.3%
Net margin
-16.4%
Return on equity
+47.5%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$236.20M$160.18M$194.62M$292.48M$211.65M$294.64M$335.00M$207.74M$181.23M$1.53M
Cost of Revenue$39.46M$63.18M$74.15M$85.57M$150.67M$296.48M$145.34M$7.77M
Operating Income$23.50M-$50.47M-$46.26M-$80.78M-$264.50M-$377.83M-$286.29M-$178.16M-$76.67M-$136.46M
Net Income-$5.34M-$69.41M-$51.92M-$94.23M-$282.02M-$384.84M-$279.66M-$143.59M-$73.67M-$135.75M
EPS (Diluted)$-0.02$-0.33$-0.28$-0.52$-1.70$-2.78$-2.36
Total Assets$376.56M$220.67M$241.70M$356.05M$529.35M$644.14M$771.20M$996.54M$364.25M$300.22M
Total Liabilities$343.95M$269.86M$272.29M$350.82M$455.34M$396.52M$376.44M$360.61M$241.67M$232.10M
Shareholders' Equity$32.61M-$49.19M-$30.58M$5.23M$74.01M$244.35M$392.88M$635.93M$122.57M$68.12M
Cash & Equivalents$184.84M$51.87M$42.92M$90.47M$149.80M$228.70M$147.45M$104.64M$70.16M$187.34M
Operating Cash Flow$67.99M-$40.66M-$23.38M-$73.15M-$252.97M-$110.39M-$257.44M-$97.49M-$56.16M$57.91M
Capital Expenditures$291.0K$33.0K$0$114.0K$59.0K$317.0K$6.66M$1.61M$1.62M$2.66M
Shares Outstanding265.42M224.85M194.58M184.14M177.00M148.07M121.67M116.89M47.61M38.62M